Background: Inconsistent findings have been reported regarding the association of C-reactive protein to albumin ratio (CAR) with survival outcome in patients with pancreatic cancer. We conducted the current meta-analysis to assess the prognostic utility of elevated baseline CAR in predicting overall survival (OS) in pancreatic cancer patients.

Methods: A comprehensively literature search was performed in the PubMed and Embase database until February 10, 2019. Studies evaluating the association between pretreatment CAR and OS among pancreatic cancer were selected. Study quality was evaluated by using the Newcastle-Ottawa Scale.

Results: Nine retrospective studies involving 1534 pancreatic cancer patients were identified. A meta-analysis using a random-effect model indicated that elevated CAR was associated with poor OS (hazard ratio 1.98; 95% confidence interval 1.58-2.48). Subgroup analysis produced similar prognostic values for OS in different geographical regions, sample sizes, thresholds of CAR, treating methods, and Newcastle-Ottawa Scale points.

Conclusion: Elevated pretreatment CAR may independently predict poor OS in pancreatic cancer patients. Pretreatment CAR is possibly a simple and cost-effective blood-derived indicator for predicting survival outcome in patients with pancreatic cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306286PMC
http://dx.doi.org/10.1097/MD.0000000000020595DOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
28
predicting survival
12
pretreatment car
12
survival pancreatic
8
survival outcome
8
outcome patients
8
patients pancreatic
8
cancer patients
8
pancreatic
7
cancer
7

Similar Publications

Both acute kidney injury and chronic kidney disease are risk factors for many outcomes of gastrointestinal bleeding (GIB). These are associated with higher mortality, longer hospitalisation, and greater need for transfusion in case of overt GIB. Our study aimed to further evaluate the role of kidney function in several clinical outcomes of GIB patients.

View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a 5-year survival rate of 12%. It has two major molecular subtypes: classical and basal, regulated by the master transcription factors (MTFs) GATA6 and ΔNp63, respectively.

Objective: This study sought to uncover the transcriptional regulatory mechanisms controlling PDAC subtype identity.

View Article and Find Full Text PDF

Deep learning-based quick MLC sequencing for MRI-guided online adaptive radiotherapy: a feasibility study for pancreatic cancer patients.

Phys Med Biol

January 2025

Department of Radiation Oncology, Division of Medical Physics and Engineering​ , UT Southwestern Medical Center, 2280 Inwood Road, Dallas, Texas, 75390-9096, UNITED STATES.

One bottleneck of MRI-guided Online Adaptive Radiotherapy (MRoART) is the time-consuming daily online replanning process. The current leaf sequencing method takes up to 10 minutes, with potential dosimetric degradation and small segment openings that increase delivery time. This work aims to replace this process with a fast deep learning-based method to provide deliverable MLC sequences almost instantaneously, potentially accelerating and enhancing online adaption.

View Article and Find Full Text PDF

Purpose: Pancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.

View Article and Find Full Text PDF

Background: Hypoxia in tumor cells is linked to increased drug resistance and more aggressive behavior. In pancreatic cancer, the tumor microenvironment is notably hypoxic and exhibits strong immunosuppressive properties. Given that immunotherapy is now approved for pancreatic cancer treatment, further understanding of how pancreatic tumor cell hypoxia influences T-cell cytotoxicityis essential.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!